# A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

> **NCT05234684** · PHASE3 · UNKNOWN · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** Orelabrutinib + R-CHOP
- **DRUG:** Placebo + R-CHOP

## Key facts

- **NCT ID:** NCT05234684
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-02
- **Primary completion:** 2024-07-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05234684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05234684, "A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05234684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*